

PRIOR AUTHORIZATION REQUEST FORM

YESCARTA®

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance: University of Utah Health Employees: 855-856-5690, Individual & Family Plans : 855-869-4769, Commercial Groups: 855-859-4892, MHC 855-885-7695

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:		

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: Yescarta® (axicabtagene ciloleucel)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section

Questions	Yes	No	Comments/Notes
1. Is the request for Yescarta® for Relapse or Refractory Large B-cell Lymphoma?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Is the request for Yescarta for Large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapsed within 12 months of first-line chemoimmunotherapy?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Is the request for Yescarta® for Relapse or Refractory Follicular Lymphoma?	<input type="checkbox"/>	<input type="checkbox"/>	
4. Is the member at least 18 years of age?	<input type="checkbox"/>	<input type="checkbox"/>	
5. Is the requesting provider in the Yescarta® REMS program?	<input type="checkbox"/>	<input type="checkbox"/>	
6. Does the member have CD-19 positive disease?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
7. Does the member meet at least one of the following: <ul style="list-style-type: none"> • No response to at least 2 lines of systemic therapy which must include an anti CD-20 therapy and an anthracycline containing regimen • Disease progression or relapse post-autologous stem cell transplant (ASCT) 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
8. Has the member been found to be negative for active infections, including Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV), and influenza?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

9. Does the member have adequate and stable kidney, liver, and cardiac function?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
10. Does documentation show the members Eastern Cooperative Oncology Group (ECOG) Performance status?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
11. If a sexually active female of reproductive age, does the member have a negative pregnancy test?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
12. Does the member have any of the following: <ul style="list-style-type: none"> • Grade 2 to 4 graft versus host disease • Presence of an autoimmune disease requiring immune suppression • History of primary central nervous system lymphoma or active CNS involvement by malignancy • Cardiac ejection fraction <50%, evidence of pericardial effusion, or clinically significant pleural effusion 	<input type="checkbox"/>	<input type="checkbox"/>	
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician's Signature:			

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy PHARM- M009
Origination Date: 04/13/2018
Reviewed/Revised Date: 06/28/2023
Next Review Date: 06/28/2024
Current Effective Date: 07/01/2023

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.